This analysis from the ALPINE trial looked at whether patient-reported outcomes (PROs) could help track disease progression in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). Patients treated with zanubrutinib (a BTK inhibitor) experienced less worsening symptoms (like nausea/vomiting, fatigue, pain, insomnia) compared to those treated with ibrutinib. Worsening symptoms were associated with the risk of early disease progression, regardless of treatment. This study shows the importance of PRO in clinical trials and its potential use to assess effective treatments for patients.

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.